BMC127 / Evogene - LARVOL DELTA

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program (PRNewswire) - "Biomica...announced positive pre-clinical in-vivo results in its immuno-oncology program for a follow-on combination of bacterial strains. In these studies, Biomica tested BMC128, which consists of four live bacterial strains derived from Biomica's drug candidates BMC121 and BMC127. Treatment with BMC128, both prior to and in combination with ICI, significantly improved anti-tumor activity in mice....Biomica's current results demonstrate that treatment with BMC128 prior to and in combination with the administration of ICI, significantly reduced tumor volume and increased animal survival compared to ICI therapy alone."

Preclinical • Oncology